Via $950M Semma takeout, Vertex moves into diabetes and cell therapy

As Vertex continues to add new therapeutic areas and modalities to its portfolio, the company will pay $950 million in cash to acquire Semma and its stem cell-derived islet program. The acquisition marks Vertex's entry into diabetes and cell therapy.

Semma Therapeutics Inc. (Cambridge, Mass.) President and CEO Bastiano

Read the full 486 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers